B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
XBIO
Xenetic BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+45.1
Score
AI commentary
News tone is mixed: the earnings release emphasized positive translational research, collaboration progress, and royalty support, while financial results showed a continuing loss and lower cash. Analyst revisions, options data, short interest, employee sentiment, and a verified post-print price reaction were unavailable; social coverage was absent. No direct operating peer set was verified, so confidence remains limited.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-11eventQ2 2026 results provide mixed read-throughMedium impact
The August 7 filing reported approximately $0.7 million of royalty revenue, up 12% year over year, but a $0.9 million net loss, cash of approximately $6.5 million, and higher G&A tied partly to the strategic review. [#SEC-8K-2026-08-07]
2026-11-11catalystStrategic-review or runway updateHigh impact
The company is continuing a strategic review while relying partly on recurring royalty revenue; any concrete update could move the stock, but timing and outcome are not disclosed in the packet.
2027-08-13catalystDNase platform and exploratory CAR-T study progressionHigh impact
ASCO preclinical data and Israeli regulatory and IRB approval for a PeriNess-led exploratory study of systemic DNase I with anti-CD19 CAR-T in large B-cell lymphoma provide a possible future clinical-development path, but remain preclinical or exploratory. [#SEC-8K-2026-08-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology